Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:684 |
Name | hepatocellular carcinoma |
Definition | A liver carcinoma that has_material_basis_in undifferentiated hepatocytes and located_in the liver. |
Source | DiseaseOntology.org |
Alt Ids | DOID:5005 |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer hepatobiliary system cancer liver cancer liver carcinoma hepatocellular carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
CTNNB1 mutant | PMED-1 | hepatocellular carcinoma | sensitive | detail... |
TP53 Y220C | CP-31398 | hepatocellular carcinoma | sensitive | detail... |
TP53 R249S | CP-31398 | hepatocellular carcinoma | sensitive | detail... |
FGFR1 pos FGFR2 pos | Fexagratinib | hepatocellular carcinoma | sensitive | detail... |
FGFR1 pos FGFR2 pos | PHA-665752 | hepatocellular carcinoma | no benefit | detail... |
NRAS mutant | Refametinib + Sorafenib | hepatocellular carcinoma | sensitive | detail... |
PIK3CA mutant | Sorafenib | hepatocellular carcinoma | decreased response | detail... |
PTEN mutant | Sorafenib | hepatocellular carcinoma | decreased response | detail... |
TSC2 mutant | Sorafenib | hepatocellular carcinoma | decreased response | detail... |
TSC1 mutant | Sorafenib | hepatocellular carcinoma | decreased response | detail... |
CTNNB1 act mut | unspecified PD-1 antibody | hepatocellular carcinoma | decreased response | detail... |
CTNNB1 act mut | unspecified PD-L1 antibody | hepatocellular carcinoma | decreased response | detail... |
CTNNB1 act mut | unspecified CTLA4 antibody | hepatocellular carcinoma | decreased response | detail... |
CTNNB1 act mut | unspecified CTLA4 antibody + unspecified PD-1 antibody | hepatocellular carcinoma | decreased response | detail... |
TP53 Y220C | SLMP53-2 | hepatocellular carcinoma | sensitive | detail... |
TP53 Y220C | SLMP53-2 + Sorafenib | hepatocellular carcinoma | sensitive | detail... |
TSC2 D1598fs TSC2 D1690fs | Everolimus | hepatocellular carcinoma | predicted - sensitive | detail... |
TSC2 E96* | Everolimus | hepatocellular carcinoma | predicted - sensitive | detail... |
TSC1 R98* | Everolimus | hepatocellular carcinoma | predicted - sensitive | detail... |
FLT3 over exp | Sorafenib | hepatocellular carcinoma | sensitive | detail... |
MLH1 negative | Dostarlimab-gxly | hepatocellular carcinoma | sensitive | detail... |
MSH6 negative | Dostarlimab-gxly | hepatocellular carcinoma | sensitive | detail... |
CTNNB1 G34R | Everolimus + Sorafenib | hepatocellular carcinoma | predicted - sensitive | detail... |
RET fusion | Selpercatinib | hepatocellular carcinoma | sensitive | detail... |
CTNNB1 S37C | WNTinib | hepatocellular carcinoma | sensitive | detail... |
CTNNB1 G34V | WNTinib | hepatocellular carcinoma | sensitive | detail... |
CTNNB1 T41A | WNTinib | hepatocellular carcinoma | sensitive | detail... |
CTNNB1 S33F | WNTinib | hepatocellular carcinoma | sensitive | detail... |
CTNNB1 S37F CTNNB1 S45Y | WNTinib | hepatocellular carcinoma | sensitive | detail... |
CTNNB1 S45F | WNTinib | hepatocellular carcinoma | sensitive | detail... |
CTNNB1 S45P | WNTinib | hepatocellular carcinoma | sensitive | detail... |
CTNNB1 mutant | WNTinib | hepatocellular carcinoma | predicted - sensitive | detail... |
CTNNB1 mut KIT V559D KIT T670I | WNTinib | hepatocellular carcinoma | predicted - sensitive | detail... |
CTNNB1 mut MAP2K1 S218D MAP2K1 S222D | WNTinib | hepatocellular carcinoma | predicted - resistant | detail... |
BRAF T529N CTNNB1 mut | WNTinib | hepatocellular carcinoma | predicted - sensitive | detail... |
CTNNB1 act mut | WNTinib | hepatocellular carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00986661 | Phase I | PV-10 | A Study to Assess PV-10 Chemoablation of Cancer of the Liver | Unknown status | USA | 0 |
NCT01015833 | Phase III | Doxorubicin Sorafenib | Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer | Completed | USA | CAN | 1 |
NCT01075113 | Phase I | Sorafenib + Vorinostat | Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer | Completed | USA | 0 |
NCT01141478 | Phase I | Sorafenib | Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria | Terminated | USA | 0 |
NCT01174121 | Phase II | Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Recruiting | USA | 0 |
NCT01177397 | Phase Ib/II | Onatasertib | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | Completed | USA | GBR | FRA | ESP | 0 |
NCT01246986 | Phase II | Galunisertib + Sorafenib Galunisertib | A Study of LY2157299 in Participants With Hepatocellular Carcinoma | Completed | USA | NZL | ITA | FRA | ESP | DEU | AUS | 0 |
NCT01306058 | Phase Ib/II | Carotuximab + Sorafenib | Sorafenib and TRC105 in Hepatocellular Cancer | Completed | USA | 0 |
NCT01356628 | Phase II | Palbociclib | A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer | Completed | USA | 0 |
NCT01421524 | Phase I | CC-122 | Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma | Completed | USA | ITA | FRA | ESP | BEL | 0 |
NCT01556490 | Phase III | Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 2 | |
NCT01567930 | Phase II | Temsirolimus | Temsirolimus as Second-line Therapy in HCC | Unknown status | USA | 0 |
NCT01624285 | Phase II | Sorafenib | Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer | Completed | USA | 0 |
NCT01628640 | Phase I | VSV-IFN-beta | Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT01642342 | Phase I | sEphB4-HSA | Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors | Terminated | USA | 0 |
NCT01655693 | Phase III | Doxorubicin | Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma (ReLive) | Completed | USA | TUR | LBN | ITA | HUN | FRA | ESP | DEU | BEL | AUT | 1 |
NCT01658878 | Phase I | Nivolumab | Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab in Subjects With Advanced Liver Cancer Anti-PD-1 HCC (Anti-Programmed-Death-1 Hepatocellular Carcinoma) | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | 6 |
NCT01666756 | Phase I | Sorafenib + YIV-906 | Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer | Completed | USA | 0 |
NCT01687673 | Phase II | Sorafenib + Temsirolimus | Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma | Completed | USA | 0 |
NCT01695005 | Phase I | LY3039478 | A Study of LY3039478 in Participants With Advanced Cancer | Completed | USA | GBR | FRA | ESP | DNK | DEU | 0 |
NCT01730937 | Phase III | Sorafenib | Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer | Active, not recruiting | USA | CAN | AUS | 2 |
NCT01754987 | Phase Ib/II | Sorafenib | A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective | Completed | USA | 0 |
NCT01755767 | Phase III | Tivantinib | Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy | Completed | USA | SWE | NZL | NLD | ITA | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 1 |
NCT01761266 | Phase III | Lenvatinib Sorafenib | A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma | Completed | USA | POL | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 10 |
NCT01774344 | Phase III | Regorafenib | Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma (RESORCE) | Completed | USA | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CHE | BRA | BEL | AUT | AUS | ARG | 6 |
NCT01775501 | Phase II | Sorafenib Fluorouracil Oxaliplatin Leucovorin | Sorafenib + mFOLFOX for Hepatocellular Carcinoma | Completed | USA | 0 |
NCT01801163 | Phase I | Sorafenib | A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC) | Withdrawn | USA | 0 |
NCT01835223 | Phase Ib/II | Tivozanib | Tivozanib in Treating Patients With Liver Cancer That is Metastatic or Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT01840592 | Phase II | Doxorubicin + Sorafenib | Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib | Active, not recruiting | USA | 0 |
NCT01849588 | FDA approved | Sorafenib | Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C | Terminated | USA | 0 |
NCT01853618 | Phase I | Tremelimumab | Tremelimumab With Chemoembolization or Ablation for Liver Cancer | Completed | USA | 0 |
NCT01887717 | Phase III | Sorafenib | Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein | Terminated | USA | ITA | GBR | FRA | ESP | BEL | 0 |
NCT01900002 | Phase II | Sorafenib | Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma (HCC) | Completed | USA | 0 |
NCT01908426 | Phase III | Cabozantinib | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | Completed | USA | TUR | ROU | POL | NZL | NLD | ITA | IRL | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
NCT01915602 | Phase II | Refametinib + Sorafenib | Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) | Completed | USA | TUR | NZL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CHE | BEL | AUT | 7 |
NCT01966445 | Phase I | GSK2849330 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors | Completed | USA | NLD | AUS | 0 |
NCT01968109 | Phase I | Nivolumab + Relatlimab Relatlimab | Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | Active, not recruiting | USA | NOR | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | AUT | AUS | 1 |
NCT01999738 | Phase I | EC1456 | Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02024087 | Phase Ib/II | Dalantercept + Sorafenib | Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | Completed | USA | 0 |
NCT02024607 | Phase Ib/II | Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer | Completed | USA | CAN | 0 |
NCT02069145 | Phase I | Ipafricept + Sorafenib | Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer | Completed | USA | 0 |
NCT02072486 | Phase I | Sorafenib | Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT02082210 | Phase Ib/II | Emibetuzumab + Ramucirumab | A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | Completed | USA | 0 |
NCT02101593 | Phase I | ADI-PEG 20 | Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer | Completed | USA | 0 |
NCT02128958 | Phase II | CF102 | Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) | Completed | USA | ROU | ISR | BGR | 1 |
NCT02143401 | Phase I | Navitoclax + Sorafenib | Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors | Active, not recruiting | USA | 0 |
NCT02151864 | Phase I | Sonidegib | LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A Cirrhosis | Completed | USA | 0 |
NCT02174549 | Phase I | Tirapazamine | Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer | Active, not recruiting | USA | 0 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02227914 | Phase Ib/II | Oprozomib Sorafenib | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | Withdrawn | USA | 0 |
NCT02232633 | Phase II | Amcasertib | A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer | Completed | CAN | 0 |
NCT02279719 | Phase Ib/II | Sorafenib Amcasertib + Sorafenib Napabucasin + Sorafenib | A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma | Completed | USA | 0 |
NCT02288507 | Phase I | Sorafenib | Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer | Withdrawn | USA | 0 |
NCT02292173 | Phase I | Sorafenib + Trametinib | Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer | Completed | USA | 0 |
NCT02314052 | Phase Ib/II | DCR-MYC | Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma | Terminated | USA | 2 |
NCT02315066 | Phase I | PF-04518600 PF-04518600 + Utomilumab | Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 | Completed | USA | NLD | FRA | 1 |
NCT02323906 | Phase Ib/II | CC-122 + Sorafenib | Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer | Terminated | USA | 0 |
NCT02406508 | Phase II | Melphalan Sorafenib | Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC | Withdrawn | USA | 0 |
NCT02423343 | Phase Ib/II | Galunisertib Nivolumab | A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma | Completed | USA | ESP | 0 |
NCT02432963 | Phase I | MVAp53 + Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Active, not recruiting | USA | 0 |
NCT02435433 | Phase III | Ramucirumab | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2) | Completed | USA | POL | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 5 |
NCT02460991 | Phase I | Sorafenib Doxorubicin | A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma | Terminated | USA | 0 |
NCT02508467 | Phase I | Fisogatinib | A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma and Cholangiocarcinoma | Completed | USA | ITA | GBR | FRA | ESP | DEU | CHE | 5 |
NCT02509507 | Phase I | Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab | Completed | USA | POL | ESP | DEU | CHE | BEL | AUT | AUS | 1 |
NCT02519348 | Phase II | Tremelimumab Durvalumab | A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma | Active, not recruiting | USA | ITA | ESP | 6 |
NCT02524119 | Phase II | Ribociclib | LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma (LEE001) | Terminated | USA | 0 |
NCT02528643 | Phase II | Enzalutamide | A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma | Completed | USA | ITA | GBR | ESP | CAN | 4 |
NCT02540291 | Phase I | E7046 | Study of E7046 in Subjects With Selected Advanced Malignancies | Terminated | USA | FRA | 0 |
NCT02560779 | Phase Ib/II | Carotuximab + Sorafenib | Trial of TRC105 and Sorafenib in Patients With HCC | Completed | USA | 0 |
NCT02562755 | Phase III | JX-594 Sorafenib | Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone | Completed | USA | NZL | ITA | ISR | GBR | FRA | DEU | CAN | AUS | 7 |
NCT02564614 | Phase I | EZN-2968 | A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC) | Completed | USA | 0 |
NCT02572687 | Phase I | Durvalumab + Ramucirumab | A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies | Completed | USA | ITA | ISR | FRA | ESP | DEU | 2 |
NCT02575339 | Phase Ib/II | Sorafenib Sapanisertib | MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma | Terminated | USA | 0 |
NCT02576509 | Phase III | Nivolumab Sorafenib | A Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma | Completed | USA | SWE | POL | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 7 |
NCT02595866 | Phase I | Pembrolizumab | Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms | Completed | USA | 0 |
NCT02597036 | Phase I | LY3127804 Ramucirumab | A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors | Completed | USA | FRA | ESP | BEL | 0 |
NCT02638909 | Phase II | Ceritinib | Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies | Terminated | USA | 0 |
NCT02642913 | Phase Ib/II | Enzalutamide Sorafenib | Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients | Completed | USA | 0 |
NCT02658019 | Phase II | Pembrolizumab | Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma | Completed | USA | 0 |
NCT02675946 | Phase I | CGX1321 CGX1321 + Pembrolizumab Cetuximab + CGX1321 + Encorafenib | CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | Unknown status | USA | 1 |
NCT02702401 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | Completed | 0 | |
NCT02702414 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) as Monotherapy in Adults With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | Completed | 0 | |
NCT02715531 | Phase I | Capecitabine Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Gemcitabine + Nab-paclitaxel Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin | A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | Completed | USA | NZL | AUS | 4 |
NCT02795429 | Phase Ib/II | Spartalizumab Capmatinib + Spartalizumab | Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC | Completed | ITA | FRA | DEU | CAN | 4 |
NCT02817633 | Phase I | Cobolimab Cobolimab + Dostarlimab-gxly + TSR-033 Cisplatin + Cobolimab + Dostarlimab-gxly + Pemetrexed Disodium Cobolimab + Dostarlimab-gxly Cobolimab + Nivolumab Cobolimab + Docetaxel Cobolimab + Docetaxel + Dostarlimab-gxly | A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | Recruiting | USA | ESP | 2 |
NCT02821754 | Phase Ib/II | Durvalumab + Tremelimumab | A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) | Completed | USA | 0 |
NCT02834780 | Phase I | H3B-6527 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma | Completed | USA | ITA | GBR | FRA | ESP | CAN | BEL | 4 |
NCT02837029 | Phase I | Nivolumab | Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer | Completed | USA | 0 |
NCT02842125 | Phase I | Ad5CMV-p53 gene + Pembrolizumab Ad5CMV-p53 gene + Capecitabine Ad5CMV-p53 gene + Nivolumab | Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer | Terminated | USA | 0 |
NCT02856425 | Phase I | Nintedanib + Pembrolizumab | Trial Of Pembrolizumab And Nintedanib (PEMBIB) | Recruiting | FRA | 0 |
NCT02859324 | Phase Ib/II | CC-122 + Nivolumab | A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC) | Completed | USA | ITA | FRA | ESP | 0 |
NCT02867592 | Phase II | Cabozantinib | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | Active, not recruiting | USA | 0 |
NCT02905188 | Phase I | GLYCAR T cells Cyclophosphamide + Fludarabine | Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) | Completed | USA | 0 |
NCT02906397 | Phase I | Galunisertib | A Phase I Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC) | Completed | USA | 0 |
NCT02939807 | Phase II | ABC294640 | A Phase II Study of ABC294640 as Second-Line Monotherapy in Patients With Advanced Hepatocellular Carcinoma | Withdrawn | USA | 0 |
NCT02940496 | Phase Ib/II | Pembrolizumab | Pembrolizumab (MK-3475) in Hepatocellular Carcinoma | Completed | USA | 0 |
NCT02947165 | Phase I | NIS793 + Spartalizumab NIS793 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | Completed | USA | ITA | DEU | CHE | CAN | AUT | 3 |
NCT02960594 | Phase I | INO-1400 + INO-9012 INO-1400 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse | Completed | USA | 0 |
NCT02988440 | Phase I | Sorafenib + Spartalizumab | Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | Completed | USA | ITA | ESP | DEU | CAN | 3 |
NCT02989870 | Phase I | Bavituximab + Sorafenib | Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma | Withdrawn | USA | 0 |
NCT03006926 | Phase I | Lenvatinib + Pembrolizumab | A Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma | Completed | USA | ITA | GBR | FRA | ESP | 2 |
NCT03017326 | Phase III | Cisplatin Carboplatin + Etoposide Gemcitabine + Oxaliplatin + Sorafenib Cisplatin + Doxorubicin + Sorafenib Cisplatin + Doxorubicin + Gemcitabine + Oxaliplatin + Sorafenib Carboplatin + Doxorubicin Irinotecan + Vincristine Sulfate Cisplatin + Doxorubicin + Fluorouracil + Vincristine Sulfate Cisplatin + Doxorubicin Carboplatin + Cisplatin + Doxorubicin | Paediatric Hepatic International Tumour Trial (PHITT) | Active, not recruiting | POL | NOR | NLD | ISR | IRL | GBR | FRA | FIN | ESP | DEU | CZE | CHE | BEL | AUT | 0 |
NCT03037437 | Phase II | Hydroxychloroquine + Sorafenib | Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer | Active, not recruiting | USA | 0 |
NCT03059147 | Phase I | SF1126 | A Study of Single Agent SF1126 Inhibitor in Patients With Advanced Hepatocellular Carcinoma | Terminated | USA | 0 |
NCT03095781 | Phase I | Pembrolizumab + XL888 | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | Completed | USA | 0 |
NCT03099564 | Phase I | Pembrolizumab | Pembrolizumab Plus Y90 Radioembolization in HCC Subjects | Active, not recruiting | USA | 0 |
NCT03132792 | Phase I | AFPc332T | AFPc332T in Advanced HCC | Active, not recruiting | USA | GBR | FRA | ESP | 0 |
NCT03143270 | Phase I | Nivolumab | A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer | Active, not recruiting | USA | 0 |
NCT03144661 | Phase I | INCB062079 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | Terminated | USA | BEL | 0 |
NCT03145558 | Phase II | Doxorubicin Tirapazamine | TATE Versus TACE in Intermediate Stage HCC (TATE) | Suspended | USA | 0 |
NCT03203304 | Phase I | Nivolumab Ipilimumab + Nivolumab | Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma | Terminated | USA | 0 |
NCT03211416 | Phase Ib/II | Pembrolizumab + Sorafenib | Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer | Active, not recruiting | USA | 0 |
NCT03222076 | Phase II | Ipilimumab + Nivolumab Nivolumab | Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956) | Completed | USA | 0 |
NCT03253289 | Phase I | Meclizine | Meclizine for Hepatocellular Carcinoma (OPTIM) | Completed | USA | 0 |
NCT03257761 | Phase I | Durvalumab + Guadecitabine | Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer | Active, not recruiting | USA | 0 |
NCT03259867 | Phase II | Nivolumab Pembrolizumab | Combination of TATE and PD-1 Inhibitor in Liver Cancer | Recruiting | USA | 0 |
NCT03264664 | Phase I | E7386 | Study of E7386 in Participants With Selected Advanced Neoplasms | Active, not recruiting | USA | GBR | 0 |
NCT03298451 | Phase III | Sorafenib Durvalumab + Tremelimumab Durvalumab | Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BRA | 10 |
NCT03299946 | Phase I | Cabozantinib + Nivolumab | Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) | Completed | USA | 0 |
NCT03316222 | Phase Ib/II | GNS561 | Study of GNS561 in Patients With Liver Cancer | Terminated | USA | FRA | BEL | 0 |
NCT03316872 | Phase II | Pembrolizumab | Study of Pembrolizumab and Radiotherapy in Liver Cancer | Active, not recruiting | CAN | 0 |
NCT03318562 | Phase II | Tomivosertib | A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC | Terminated | USA | 0 |
NCT03319459 | Phase I | FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT03347292 | Phase I | Pembrolizumab + Regorafenib | Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC | Completed | USA | DEU | 0 |
NCT03382886 | Phase I | Bevacizumab + Nivolumab | Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma (NUANCE) | Terminated | USA | 0 |
NCT03383458 | Phase III | Nivolumab | A Phase 3 Study of Nivolumab in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Active, not recruiting | USA | ROU | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUT | AUS | ARG | 10 |
NCT03412773 | Phase III | Tislelizumab Sorafenib | Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCC | Completed | USA | POL | ITA | GBR | FRA | ESP | DEU | CZE | 3 |
NCT03416335 | Phase Ib/II | DSP-0509 DSP-0509 + Pembrolizumab | A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile | Terminated | USA | 0 |
NCT03419897 | Phase II | Tislelizumab | Study of BGB-A317 in Patients With Previously Treated Unresectable HCC | Completed | POL | ITA | GBR | FRA | ESP | DEU | 2 |
NCT03433703 | Phase II | Lenvatinib | Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC) | Terminated | USA | 0 |
NCT03434379 | Phase III | Atezolizumab + Bevacizumab Sorafenib | A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150] | Completed | USA | POL | ITA | GBR | FRA | ESP | DEU | CZE | CAN | AUS | 7 |
NCT03439891 | Phase II | Nivolumab + Sorafenib | Sorafenib and Nivolumab as First-Line Therapy in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer | Active, not recruiting | USA | 0 |
NCT03441100 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin IMA202 | TCR-engineered T Cells in NSCLC and HCC Patients | Completed | USA | DEU | 0 |
NCT03475953 | Phase Ib/II | Avelumab + Regorafenib | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) | Recruiting | FRA | 0 |
NCT03482102 | Phase II | Durvalumab + Tremelimumab | Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer | Recruiting | USA | 0 |
NCT03511222 | Phase I | Pembrolizumab + Vorolanib Nivolumab + Vorolanib | Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | Terminated | USA | 0 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
NCT03519997 | Phase II | Bavituximab + Pembrolizumab | A Phase II Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma | Active, not recruiting | USA | 0 |
NCT03533582 | Phase II | Cisplatin + Doxorubicin + Gemcitabine + Oxaliplatin + Sorafenib Cisplatin + Doxorubicin + Fluorouracil + Vincristine Sulfate Carboplatin + Cisplatin + Doxorubicin + Etoposide Carboplatin + Cisplatin + Doxorubicin + Irinotecan + Vincristine Sulfate Cisplatin Cisplatin + Doxorubicin + Sorafenib Cisplatin + Doxorubicin Carboplatin + Cisplatin + Doxorubicin | Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery | Active, not recruiting | USA | NZL | CAN | AUS | 2 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03539822 | Phase I | Cabozantinib + Durvalumab | Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA) | Active, not recruiting | USA | 0 |
NCT03556228 | Phase I | VMD-928 | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | Recruiting | USA | 1 |
NCT03563170 | Phase Ib/II | Aldoxorubicin + Avelumab + Capecitabine + Cetuximab + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Sorafenib Sorafenib | QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine | Withdrawn | USA | 0 |
NCT03582618 | Phase II | CVM-1118 + Sorafenib | CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma | Terminated | USA | 1 |
NCT03630640 | Phase II | Nivolumab | Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation (NIVOLEP) | Completed | FRA | 0 |
NCT03637764 | Phase Ib/II | Atezolizumab + Isatuximab Isatuximab | Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies | Terminated | USA | NLD | ITA | ESP | CZE | CAN | BEL | 1 |
NCT03638141 | Phase II | Durvalumab + Tremelimumab | CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab | Completed | USA | 0 |
NCT03647163 | Phase I | Pembrolizumab + VSV-hIFNbeta-NIS | Combination Therapy With Intravenous VSV-IFNbeta-NIS and Pembrolizumab in Refractory NSCLC and HCC | Recruiting | USA | 0 |
NCT03655002 | Phase I | Cyclophosphamide + IRX-2 + Nivolumab | IRX-2, Cyclophosphamide, and Nivolumab in Treating Participants With Recurrent or Metastatic and Refractory Liver Cancer | Active, not recruiting | USA | 0 |
NCT03656718 | Phase Ib/II | Nivolumab + rHuPH20 | A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) | Active, not recruiting | USA | POL | NZL | NLD | ITA | GBR | FRA | ESP | BRA | ARG | 2 |
NCT03665129 | Phase I | Avdoralimab + Durvalumab | IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001) | Terminated | USA | FRA | 0 |
NCT03680508 | Phase II | Cobolimab + Dostarlimab-gxly | TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer | Active, not recruiting | USA | 0 |
NCT03682276 | Phase Ib/II | Ipilimumab + Nivolumab | Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma (PRIME-HCC) | Recruiting | GBR | 0 |
NCT03684811 | Phase Ib/II | Cisplatin + Gemcitabine + Olutasidenib Azacitidine + Olutasidenib Olutasidenib Nivolumab + Olutasidenib | A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation | Completed | USA | GBR | FRA | ESP | AUS | 1 |
NCT03695250 | Phase Ib/II | Linrodostat + Nivolumab | BMS-986205 and Nivolumab as First Line Therapy in Treating Patients With Liver Cancer | Terminated | USA | 0 |
NCT03713593 | Phase III | Lenvatinib Lenvatinib + Pembrolizumab | Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) | Completed | USA | TUR | POL | NZL | ITA | IRL | GBR | FRA | ESP | DEU | CAN | AUS | 9 |
NCT03733990 | Phase Ib/II | FP-1305 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Completed | USA | NLD | GBR | FRA | FIN | ESP | 0 |
NCT03735628 | Phase Ib/II | Copanlisib + Nivolumab | An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | CAN | 0 |
NCT03752398 | Phase I | Izuralimab | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Completed | USA | 0 |
NCT03753659 | Phase II | Pembrolizumab | IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) | Completed | DEU | 0 |
NCT03755791 | Phase III | Cabozantinib Sorafenib Atezolizumab + Cabozantinib | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312) | Active, not recruiting | USA | TUR | ROU | POL | NZL | NLD | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 12 |
NCT03778957 | Phase III | Durvalumab Bevacizumab + Durvalumab | A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1) | Active, not recruiting | USA | ITA | FRA | ESP | CAN | BRA | AUS | 11 |
NCT03781934 | Phase Ib/II | MIV-818 | A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations | Active, not recruiting | GBR | ESP | BEL | 1 |
NCT03781960 | Phase II | Abemaciclib + Nivolumab | Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma | Terminated | USA | 0 |
NCT03785210 | Phase II | Nivolumab + Tadalafil + Vancomycin | Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers | Completed | USA | 0 |
NCT03812562 | Phase I | Nivolumab | Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection | Terminated | USA | 0 |
NCT03816345 | Phase I | Nivolumab | Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | Recruiting | USA | CAN | 0 |
NCT03821935 | Phase I | ABBV-151 ABBV-151 + Budigalimab | Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | ISR | FRA | ESP | CAN | BEL | AUS | 4 |
NCT03829501 | Phase Ib/II | Atezolizumab + KY1044 KY1044 | Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer | Terminated | USA | POL | ITA | HUN | GBR | 1 |
NCT03836352 | Phase II | Maveropepimut-S + Pembrolizumab Cyclophosphamide + Maveropepimut-S + Pembrolizumab | Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT03847428 | Phase III | Durvalumab Bevacizumab + Durvalumab | Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment (EMERALD-2) | Active, not recruiting | USA | TUR | POL | ITA | FRA | DEU | CAN | BRA | AUT | AUS | 14 |
NCT03849469 | Phase I | Pembrolizumab + XmAb22841 XmAb22841 | A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) | Completed | USA | 0 |
NCT03867084 | Phase III | Pembrolizumab | Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937) | Active, not recruiting | USA | TUR | SWE | POL | NZL | NOR | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BRA | BGR | BEL | AUS | ARG | 9 |
NCT03897543 | Phase Ib/II | ABX196 + Nivolumab | ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma | Recruiting | USA | 0 |
NCT03908840 | Phase I | TBI-302 | Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma | Unknown status | USA | 0 |
NCT03916627 | Phase II | Cemiplimab | Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC | Recruiting | USA | 0 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Completed | USA | FRA | BEL | AUS | 1 |
NCT03937830 | Phase II | Bevacizumab + Doxorubicin + Durvalumab | Combined Treatment of Durvalumab, Bevacizumab, and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma | Recruiting | USA | 0 |
NCT03942328 | Phase II | Atezolizumab + Bevacizumab + PCV13 vaccine PCV13 vaccine | Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer | Recruiting | USA | 0 |
NCT03964233 | Phase I | BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab | A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) | Active, not recruiting | USA | NLD | HUN | GBR | FRA | ESP | DEU | BEL | AUS | 2 |
NCT03970616 | Phase Ib/II | Durvalumab + Tivozanib | A Study of Tivozanib in Combination With Durvalumab in Subjects With Untreated Advanced Hepatocellular Carcinoma | Terminated | USA | 0 |
NCT03993873 | Phase Ib/II | Elzovantinib | Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1) | Active, not recruiting | USA | FRA | ESP | 1 |
NCT03998033 | Phase Ib/II | ET140202 | Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma | Terminated | USA | 0 |
NCT04008797 | Phase I | Lenvatinib E7386 + Lenvatinib | A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor | Recruiting | USA | FRA | 3 |
NCT04020185 | Phase Ib/II | IMSA101 + unspecified PD-L1 antibody IMSA101 + unspecified PD-1 antibody IMSA101 | Safety and Efficacy Study of IMSA101 in Refractory Malignancies | Completed | USA | 0 |
NCT04039607 | Phase III | Lenvatinib Sorafenib Ipilimumab + Nivolumab | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (CheckMate 9DW) | Active, not recruiting | USA | ROU | POL | NZL | ITA | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
NCT04050462 | Phase II | BMS-986253 + Nivolumab Nivolumab Cabiralizumab + Nivolumab | A Phase II, Randomized, Controlled Trial of Nivolumab in Combination With BMS-986253 or Cabiralizumab in Advanced Hepatocellular Carcinoma (HCC) Patients | Active, not recruiting | USA | 0 |
NCT04095273 | Phase I | Elimusertib + Pembrolizumab | Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug | Completed | USA | GBR | ESP | DEU | CHE | 0 |
NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT04102098 | Phase III | Atezolizumab + Bevacizumab | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation (IMbrave050) | Active, not recruiting | USA | TUR | POL | NZL | NLD | ITA | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | 11 |
NCT04112498 | Phase I | Nivolumab + Relatlimab + rHuPH20 | A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab | Completed | USA | 0 |
NCT04114136 | Phase II | Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT04123379 | Phase II | BMS-813160 + Nivolumab Nivolumab BMS-986253 + Nivolumab | Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) | Completed | USA | 0 |
NCT04134312 | Phase I | MVA-BN-Brachyury | A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer | Completed | USA | 0 |
NCT04134559 | Phase II | Pembrolizumab | Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma | Recruiting | USA | 0 |
NCT04140526 | Phase Ib/II | ONC-392 ONC-392 + Pembrolizumab | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Recruiting | USA | AUS | 0 |
NCT04158700 | Phase Ib/II | LY3200882 + Pembrolizumab | A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer | Withdrawn | USA | FRA | ESP | 0 |
NCT04170556 | Phase Ib/II | Nivolumab + Regorafenib | Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING) (GOING) | Completed | ESP | 0 |
NCT04175912 | Phase II | Carboplatin + MLN4924 + Paclitaxel MLN4924 | Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver | Active, not recruiting | USA | 0 |
NCT04194775 | Phase III | CS1003 + Lenvatinib Lenvatinib | A Study of CS1003 in Subjects With Advanced Hepatocellular Carcinoma | Active, not recruiting | USA | POL | ITA | ESP | 2 |
NCT04204850 | Phase II | Cabozantinib | Cabozantinib to Treat of Recurrent Liver Cancer Post Transplant (CaboTx) | Recruiting | CAN | 0 |
NCT04224636 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab (DEMAND) | Recruiting | DEU | 0 |
NCT04246177 | Phase III | Lenvatinib + Pembrolizumab | Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) | Active, not recruiting | USA | TUR | NZL | NOR | NLD | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DNK | DEU | BRA | AUS | 11 |
NCT04250597 | Phase I | GNX102 | Study of GNX102 in Patients With Advanced Solid Tumors | Terminated | USA | 1 |
NCT04260802 | Phase Ib/II | OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | Recruiting | CAN | 0 |
NCT04268888 | Phase II | Nivolumab | Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC (TACE-3) | Recruiting | GBR | 0 |
NCT04282018 | Phase Ib/II | BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Completed | AUS | 1 |
NCT04282044 | Phase I | CRX100 | Study of CRX100 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04291105 | Phase II | Cemiplimab + VSV-hIFNbeta-NIS | Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | Recruiting | USA | BRA | 0 |
NCT04311710 | Phase Ib/II | Ipilimumab + Nivolumab Ipilimumab + Nivolumab + rHuPH20 | A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U) | Terminated | USA | NZL | ITA | 0 |
NCT04316182 | Phase II | Cabozantinib | Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION) (ACTION) | Completed | ESP | 0 |
NCT04327700 | Phase II | Regorafenib | Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib | Terminated | USA | 0 |
NCT04336241 | Phase I | Nivolumab + RP2 RP2 | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | Recruiting | GBR | ESP | 0 |
NCT04338685 | Phase I | RO7119929 + Tocilizumab | A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases | Completed | USA | ESP | DNK | 3 |
NCT04340193 | Phase III | Ipilimumab + Nivolumab Nivolumab | A Study of Nivolumab and Ipilimumab in Combination With Transarterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer (CheckMate 74W) | Terminated | USA | POL | ITA | FRA | ESP | DEU | CZE | CAN | BEL | AUT | AUS | 8 |
NCT04358185 | Phase I | Itacitinib | Itacitinib in Advanced Hepatocellular Carcinoma (JAKaL) | Active, not recruiting | GBR | 0 |
NCT04374877 | Phase I | SRF388 | Study of SRF388 in Patients With Advanced Solid Tumors | Recruiting | USA | 2 |
NCT04423029 | Phase Ib/II | DF6002 DF6002 + Nivolumab | A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 0 |
NCT04429542 | Phase I | BCA101 BCA101 + Pembrolizumab | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | Recruiting | USA | CAN | AUS | 0 |
NCT04430452 | Phase II | Durvalumab Durvalumab + Tremelimumab | Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for the Treatment of Liver Cancer After Progression on Prior PD-1 Inhibition | Recruiting | USA | 0 |
NCT04435977 | Phase II | Cabozantinib | Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma (Immunocabo) | Unknown status | ITA | 0 |
NCT04442581 | Phase II | Cabozantinib + Pembrolizumab | Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | Terminated | USA | 0 |
NCT04454762 | Phase II | Cabozantinib | A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function (CaboCHILD) | Unknown status | DEU | 0 |
NCT04472767 | Phase II | Cabozantinib + Ipilimumab + Nivolumab | Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | Recruiting | USA | 0 |
NCT04476329 | Phase II | Regorafenib | Optimization for Regorafenib in HCC (ReDos HCC) | Terminated | USA | 0 |
NCT04487067 | Phase III | Atezolizumab + Bevacizumab | A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista (AMETHISTA) | Completed | ITA | 0 |
NCT04497038 | Phase Ib/II | Cabozantinib | Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy | Terminated | USA | 0 |
NCT04502082 | Phase Ib/II | ET140203 | Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ET121) | Terminated | USA | 0 |
NCT04505839 | Phase I | STP1002 | First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors | Completed | USA | 0 |
NCT04511455 | Phase II | Cabozantinib | A Phase II, Non-randomized, Single Arm, Translational Study of Cabozantinib for Patients With Hepatocellular Carcinoma (HCC) Refractory to Lenvatinib Treatment | Active, not recruiting | DEU | 0 |
NCT04514484 | Phase I | Cabozantinib + Nivolumab | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | Active, not recruiting | USA | 0 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04521621 | Phase Ib/II | Coxsackievirus A21 + Pembrolizumab | A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | Terminated | USA | POL | NOR | ITA | ISR | HUN | FRA | ESP | DEU | CAN | 4 |
NCT04522544 | Phase II | Durvalumab + Tremelimumab | Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner Design | Recruiting | DEU | 0 |
NCT04522908 | Phase II | Cabozantinib | Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Compensated Liver Cirrhosis | Active, not recruiting | DEU | 0 |
NCT04524871 | Phase Ib/II | Atezolizumab + Bevacizumab + Tocilizumab Atezolizumab + Bevacizumab + Tiragolumab Atezolizumab + Bevacizumab | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) | Recruiting | USA | NZL | ISR | FRA | 3 |
NCT04541173 | Phase II | Atezolizumab + Bevacizumab | Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC) | Terminated | USA | 0 |
NCT04563338 | Phase II | Atezolizumab Atezolizumab + Bevacizumab | An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) | Recruiting | CAN | 0 |
NCT04567615 | Phase II | Nivolumab Nivolumab + Relatlimab | A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors | Active, not recruiting | TUR | ROU | POL | NZL | FRA | ESP | CZE | BRA | ARG | 8 |
NCT04605731 | Phase I | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer | Recruiting | USA | 0 |
NCT04606381 | Phase I | Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Lazertinib + rHuPH20 Amivantamab-vmjw Amivantamab-vmjw + rHuPH20 | A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA) | Active, not recruiting | USA | GBR | CAN | 1 |
NCT04634357 | Phase Ib/II | ET140203 | ET140203 T-Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma (ARYA-2) | Recruiting | USA | 0 |
NCT04658147 | Phase I | Nivolumab + Relatlimab Nivolumab | Feasibility and Efficacy of Perioperative Nivolumab With or Without Neoadjuvant Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) | Recruiting | USA | 0 |
NCT04676633 | Phase I | Cotsiranib | Open-Label Study for Safety, Tolerability, PK and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy | Completed | USA | 0 |
NCT04678908 | Phase I | HB0025 | A Study of Injection HB0025 in Patients With Advanced Solid Tumors | Unknown status | USA | 1 |
NCT04696055 | Phase II | Pembrolizumab + Regorafenib | Pilot Study of Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors | Completed | USA | ITA | ISR | FRA | ESP | DEU | 2 |
NCT04710641 | Phase II | CEBPA-51 + Sorafenib Sorafenib | Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone (OUTREACH2) | Active, not recruiting | USA | 1 |
NCT04717375 | Phase Ib/II | BND-22 | Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors | Recruiting | USA | ISR | GBR | CAN | 0 |
NCT04721132 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer | Active, not recruiting | USA | 0 |
NCT04727307 | Phase II | Atezolizumab + Bevacizumab | Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial (AB-LATE02) | Recruiting | FRA | 0 |
NCT04732286 | Phase III | Atezolizumab + Bevacizumab | A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy | Completed | ESP | 0 |
NCT04740307 | Phase II | Lenvatinib + MK-1308A | Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004) | Active, not recruiting | USA | POL | ITA | ESP | CHE | 4 |
NCT04752215 | Phase I | BI 765049 + Ezabenlimab BI 765049 | A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface | Active, not recruiting | USA | CAN | 0 |
NCT04767906 | Phase II | Cabozantinib | Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors (CaPture) | Recruiting | DEU | 0 |
NCT04770896 | Phase III | Atezolizumab + Lenvatinib Lenvatinib + Sorafenib Atezolizumab + Sorafenib | A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab (IMbrave251) | Active, not recruiting | TUR | SVN | ITA | ISR | HRV | GRC | GBR | FRA | FIN | EST | ESP | DEU | CHE | CAN | BRA | BGR | BEL | AUT | 12 |
NCT04777708 | Phase I | BO-112 + Pembrolizumab | BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer | Terminated | USA | 0 |
NCT04777851 | Phase III | Pembrolizumab + Regorafenib | Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7 (REPLACE) | Recruiting | USA | TUR | ROU | ITA | FRA | ESP | DEU | BEL | 6 |
NCT04787042 | Phase Ib/II | Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | Active, not recruiting | USA | 0 |
NCT04798781 | Phase II | Pembrolizumab + Telatinib | Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma | Active, not recruiting | USA | 0 |
NCT04803994 | Phase III | Atezolizumab + Bevacizumab | The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | Recruiting | ITA | FRA | ESP | DEU | AUT | 1 |
NCT04823403 | Phase I | Ipilimumab + Nivolumab | Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma (HIPANIV) | Recruiting | FRA | 0 |
NCT04828486 | Phase II | Futibatinib + Pembrolizumab | Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer | Recruiting | USA | 0 |
NCT04829383 | Phase II | Atezolizumab + Bevacizumab | A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma (AB7) | Active, not recruiting | USA | 0 |
NCT04851119 | Phase Ib/II | BC2059 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Recruiting | USA | 0 |
NCT04857684 | Phase I | Atezolizumab + Bevacizumab | SBRT + Atezolizumab + Bevacizumab in Resectable HCC | Recruiting | USA | 0 |
NCT04864054 | Phase Ib/II | ECT204 | T-Cell Therapy (ECT204) in Adults With Advanced HCC (ARYA-3) | Recruiting | USA | 0 |
NCT04878484 | Phase I | TCRT-ESO-A2 | Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors | Withdrawn | 0 | |
NCT04902443 | Phase I | Nivolumab + Pomalidomide | Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV | Recruiting | USA | 0 |
NCT04914286 | Phase Ib/II | GFH018 + Toripalimab-tpzi | A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors | Completed | AUS | 1 |
NCT04943900 | Phase I | BMS-986416 + Nivolumab BMS-986416 | A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors | Active, not recruiting | USA | NLD | CAN | BEL | ARG | 2 |
NCT04958239 | Phase I | BI 765179 + Ezabenlimab BI 765179 | A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer | Recruiting | USA | NLD | ITA | ISR | FRA | ESP | DEU | CZE | BRA | BEL | AUS | 4 |
NCT04965714 | Phase II | ADI-PEG 20 + Nivolumab | Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer | Withdrawn | USA | 0 |
NCT04976634 | Phase II | Belzutifan + Lenvatinib + Pembrolizumab | Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) | Recruiting | USA | NZL | NLD | ISR | FRA | ESP | BEL | AUS | 2 |
NCT04989387 | Phase I | INCA00186 + Retifanlimab INCA00186 + INCB106385 INCA00186 + INCB106385 + Retifanlimab INCA00186 | Study of INCA 0186 in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | NLD | GBR | ESP | BEL | AUT | 0 |
NCT05006794 | Phase I | GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | Recruiting | USA | ISR | 0 |
NCT05007106 | Phase II | MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | FRA | ESP | DEU | CAN | 5 |
NCT05027425 | Phase II | Durvalumab + Tremelimumab | Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant | Recruiting | USA | 0 |
NCT05038150 | Phase I | SGN1 | Study of SGN1 in Patients With Advanced Solid Tumor | Recruiting | USA | 1 |
NCT05039736 | Phase II | Cabozantinib + Nivolumab | A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy | Withdrawn | 0 | |
NCT05043714 | Phase I | NG-641 + Nivolumab | Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NEBULA) | Active, not recruiting | USA | GBR | 0 |
NCT05057013 | Phase Ib/II | HMBD-001 | HMBD-001 in Advanced HER3 Positive Solid Tumours | Recruiting | GBR | 0 |
NCT05063565 | Phase II | Durvalumab + Tremelimumab + Yttrium-90 microsphere therapy | TheraSphere With and Without Durvalumab and Tremelimumab for HCC (ROWAN) | Recruiting | USA | FRA | ESP | 0 |
NCT05070247 | Phase I | TAK-500 Pembrolizumab + TAK-500 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05086692 | Phase Ib/II | MDNA11 + Pembrolizumab | A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) | Recruiting | USA | CAN | AUS | 1 |
NCT05091346 | Phase Ib/II | E7386 + Pembrolizumab | A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors | Completed | USA | GBR | ESP | 1 |
NCT05092373 | Phase I | Cabozantinib Atezolizumab + Nab-paclitaxel | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | Recruiting | USA | 0 |
NCT05093608 | Phase I | Atezolizumab + Bevacizumab + Selinexor | SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma | Terminated | USA | 0 |
NCT05096715 | Phase I | Atezolizumab + Bevacizumab | Atezolizumab+Bevacizumab+SBRT in Unresectable HCC | Recruiting | USA | 0 |
NCT05101629 | Phase II | Lenvatinib + Pembrolizumab | Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab Therapy | Active, not recruiting | DEU | 0 |
NCT05103345 | Phase I | SGN1 | Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor | Recruiting | 2 | |
NCT05103904 | Phase II | Lenvatinib | Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant | Recruiting | USA | 0 |
NCT05104567 | Phase II | Cetuximab + THOR-707 Pembrolizumab + THOR-707 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) | Terminated | USA | NLD | ITA | FRA | ESP | BEL | 3 |
NCT05109052 | Phase Ib/II | Atezolizumab + Bevacizumab + PXS-5505 | Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma | Withdrawn | USA | 0 |
NCT05109442 | Phase Ib/II | AFM24 + Atezolizumab | Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers | Recruiting | USA | POL | GBR | ESP | 1 |
NCT05113186 | Phase II | Lenvatinib | Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative (LENVABLA) | Active, not recruiting | FRA | 0 |
NCT05118841 | Phase I | ZX-4081 | Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT05120271 | Phase Ib/II | BOXR1030 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (DUET-1) | Recruiting | USA | 0 |
NCT05168163 | Phase II | Atezolizumab + Cabozantinib Cabozantinib Atezolizumab + Lenvatinib Lenvatinib | Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer | Recruiting | USA | 0 |
NCT05171335 | Phase II | Lenvatinib | Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients | Enrolling by invitation | USA | 0 |
NCT05176665 | Phase Ib/II | EMB-01 | EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers | Recruiting | USA | 1 |
NCT05178043 | Phase II | Ascrinvacumab + Nivolumab | GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma | Active, not recruiting | USA | 0 |
NCT05185505 | FDA approved | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria | Recruiting | USA | 0 |
NCT05185739 | Phase II | Lenvatinib + Pembrolizumab Lenvatinib Pembrolizumab | Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC) (PRIMER-1) | Recruiting | GBR | 0 |
NCT05194293 | Phase II | Durvalumab + Regorafenib | Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer | Recruiting | USA | 0 |
NCT05201404 | Phase III | CF102 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis (LIVERATION) | Recruiting | USA | SVK | ROU | POL | ISR | BGR | 3 |
NCT05211323 | Phase II | Cisplatin + Gemcitabine Atezolizumab + Bevacizumab + Cisplatin + Gemcitabine | A Study to Determine Whether Chemotherapy, Bevazicumab, and Atezolizumab is Better Than Chemotherapy Alone in Patients With Advanced Liver Cancer | Active, not recruiting | USA | 0 |
NCT05212922 | Phase II | Toripalimab-tpzi + YH001 | A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC (YH001) | Withdrawn | AUT | AUS | 3 |
NCT05220722 | Phase Ib/II | Pembrolizumab + SD-101 Ipilimumab + Nivolumab + SD-101 | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | Active, not recruiting | USA | 0 |
NCT05223816 | Phase II | Nivolumab + VG161 VG161 | An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma | Recruiting | USA | 0 |
NCT05228015 | Phase I | IK-930 | Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | GBR | AUS | 0 |
NCT05229601 | Phase I | HFB301001 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | Active, not recruiting | USA | ESP | 0 |
NCT05249426 | Phase I | Cetuximab + Effi-DEM + Ezabenlimab BI 836880 + Effi-DEM + Ezabenlimab Effi-DEM + Ezabenlimab | A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer | Active, not recruiting | USA | ROU | POL | GBR | FRA | ESP | 5 |
NCT05249569 | Phase II | Avelumab + Axitinib + Bavituximab | Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma | Terminated | USA | 0 |
NCT05256381 | Phase II | Pembrolizumab + SOT101 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | Active, not recruiting | USA | POL | ITA | HUN | FRA | ESP | CZE | BEL | 1 |
NCT05263180 | Phase I | EMB-09 | A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. | Recruiting | AUS | 1 |
NCT05269381 | Phase I | Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) | Recruiting | USA | 0 |
NCT05293496 | Phase I | MGC018 + MGD019 | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05301842 | Phase III | Durvalumab + Lenvatinib + Tremelimumab Durvalumab + Tremelimumab | Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC (EMERALD-3) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BRA | BEL | 15 |
NCT05327738 | Phase II | Atezolizumab + Cabozantinib + Yttrium-90 microsphere therapy | Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma | Withdrawn | 0 | |
NCT05337137 | Phase Ib/II | Bevacizumab + Nivolumab + Relatlimab Bevacizumab + Nivolumab | A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer (RELATIVITY-106) | Recruiting | USA | POL | ITA | FRA | ESP | DEU | CAN | AUS | 7 |
NCT05345678 | Expanded access | Durvalumab + Tremelimumab | Himalaya Early Access Program | Approved for marketing | USA | 0 |
NCT05358379 | Phase Ib/II | CYC140 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | Recruiting | USA | ESP | 1 |
NCT05359861 | Phase II | Atezolizumab + Bevacizumab + SRF388 Atezolizumab + Bevacizumab | Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma | Active, not recruiting | USA | AUS | 2 |
NCT05366829 | Phase II | Tislelizumab | Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma | Recruiting | USA | 0 |
NCT05417321 | Phase Ib/II | HB0036 | A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05417932 | Phase Ib/II | SCG101 | A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma | Recruiting | USA | 2 |
NCT05438420 | Phase Ib/II | Pembrolizumab + Q702 | Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05440708 | Phase Ib/II | Atezolizumab + Bevacizumab + C188-9 C188-9 C188-9 + Pembrolizumab | A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | Recruiting | USA | 0 |
NCT05440864 | Phase II | Durvalumab + Tremelimumab Durvalumab | Durvalumab and Tremelimumab in Resectable HCC ((NEOTOMA)) | Recruiting | ITA | ESP | CAN | 0 |
NCT05448677 | Phase II | Atezolizumab + Bevacizumab Atezolizumab + Bevacizumab + GNS561 | Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma (ABE-LIVER) | Terminated | FRA | 0 |
NCT05450562 | Phase Ib/II | Atezolizumab + SAR444200 SAR444200 | Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors | Recruiting | USA | CAN | 3 |
NCT05451043 | Phase II | Cisplatin + Durvalumab + Gemcitabine + Propranolol + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Propranolol + Tremelimumab Durvalumab + Propranolol + Tremelimumab | Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) | Recruiting | CAN | 0 |
NCT05468359 | Phase Ib/II | Atezolizumab + Bevacizumab + Cyclophosphamide + Sorafenib | Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | Recruiting | USA | 0 |
NCT05482516 | Phase III | Atezolizumab + Bevacizumab | Evaluating Novel Therapies in ctDNA Positive GI Cancers (MRD-GI) | Recruiting | USA | 0 |
NCT05488522 | Phase I | Atezolizumab + Bevacizumab | SBRT With Atezo/Bev for HCC | Recruiting | USA | 0 |
NCT05496595 | Phase I | DCBY02 | DCBY02 or DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT05497453 | Phase Ib/II | OTX-2002 | A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene (MYCHELANGELO I) | Recruiting | USA | 4 |
NCT05528952 | Phase II | Atezolizumab + Bevacizumab Atezolizumab + Bevacizumab + UCPVax | Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma (TERTIO) | Recruiting | FRA | 0 |
NCT05537402 | Phase II | Atezolizumab + Bevacizumab | LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC (LOST- B) Trial (LOST-B) | Recruiting | USA | 0 |
NCT05546879 | Phase I | Atezolizumab + Bevacizumab + NP137 | Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable Hepatocellular Carcinoma (Liver-NET1) | Recruiting | FRA | 0 |
NCT05584670 | Phase Ib/II | SAR445877 | A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | Recruiting | USA | NLD | ISR | ESP | 0 |
NCT05620134 | Phase Ib/II | JK08 | A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Active, not recruiting | ESP | BEL | 0 |
NCT05620771 | Phase II | Yttrium-90 microsphere therapy Atezolizumab + Bevacizumab | Therasphere and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk | Recruiting | USA | 0 |
NCT05622071 | Phase II | Tislelizumab | Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions (HESTIA) | Recruiting | FRA | 0 |
NCT05622136 | Phase II | Regorafenib | Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma (STRAT-aHCC) | Recruiting | BRA | 0 |
NCT05630937 | Phase Ib/II | NMS-01940153E | Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy | Completed | USA | ITA | ESP | 0 |
NCT05652855 | Phase Ib/II | MHB088C | Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05665348 | Phase II | Atezolizumab + Bevacizumab Atezolizumab + Bevacizumab + Ipilimumab | Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy (TRIPLET) | Recruiting | FRA | 0 |
NCT05669339 | Phase I | Irinotecan + Sonidegib + Sorafenib | AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma | Recruiting | USA | 0 |
NCT05690048 | Phase II | Atezolizumab + Bevacizumab Atezolizumab + Bevacizumab + Fecal microbiota + Vancomycin | Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA) (FLORA) | Not yet recruiting | DEU | 0 |
NCT05701488 | Phase I | Durvalumab + Tremelimumab | SIRT With Tremelimumab and Durvalumab for Resectable HCC | Recruiting | USA | 0 |
NCT05717400 | FDA approved | Atezolizumab + Bevacizumab | Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy | Terminated | USA | 0 |
NCT05720117 | Phase I | PYX-201 | Study of PYX-201 in Solid Tumors | Recruiting | USA | ESP | BEL | 0 |
NCT05724563 | Phase II | AB154 + Zimberelimab | Domvanalimab and Zimberelimab in Advanced Liver Cancers | Recruiting | USA | 0 |
NCT05733598 | Phase II | Atezolizumab + Bevacizumab + RP3 | RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC | Recruiting | USA | 0 |
NCT05750030 | Phase II | Atezolizumab + Bevacizumab + Fecal microbiota | FMT in IT-refractory HCC - FAB-HCC Pilot Study | Recruiting | AUT | 0 |
NCT05757492 | Phase Ib/II | CHS-006 + Toripalimab-tpzi | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT05776875 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC | Recruiting | USA | 0 |
NCT05785754 | Phase I | DCSZ11 | DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | AUS | 2 |
NCT05797805 | Phase Ib/II | BC2059 BC2059 + Pembrolizumab | A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma | Recruiting | USA | CAN | 0 |
NCT05822752 | Phase II | Lenvatinib Sorafenib ABBV-151 + Budigalimab | Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) | Active, not recruiting | USA | ITA | FRA | ESP | 3 |
NCT05844046 | Phase II | Bevacizumab + Durvalumab + Tremelimumab | Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients (MONTBLANC) | Recruiting | DEU | 0 |
NCT05879822 | Phase II | INCB099280 | A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive | Active, not recruiting | TUR | ROU | NZL | HUN | GRC | BRA | 3 |
NCT05883644 | Phase III | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) (SIERRA) | Recruiting | USA | ITA | FRA | ESP | DEU | 5 |
NCT05901194 | Phase Ib/II | Lenvatinib | Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma (Ta-Len-Tra) | Not yet recruiting | FRA | 0 |
NCT05904496 | Phase I | BGB-30813 BGB-30813 + Tislelizumab | A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ESP | AUS | 0 |
NCT05904886 | Phase III | Atezolizumab + Bevacizumab + Tiragolumab Atezolizumab + Bevacizumab | A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) (SKYSCRAPER-14) | Recruiting | USA | TUR | POL | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BRA | BEL | 14 |
NCT05908786 | Phase Ib/II | Bevacizumab + RO7247669 Atezolizumab + Bevacizumab + Tiragolumab Atezolizumab + Bevacizumab | A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma | Recruiting | USA | NZL | GBR | FRA | ESP | DEU | AUT | 2 |
NCT05909995 | Phase I | INCB099280 + Ipilimumab | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors | Active, not recruiting | USA | CAN | 1 |
NCT05985083 | Phase I | IMM47 | A Study Of IMM47 In Subjects With Advanced Solid Tumors | Recruiting | AUS | 0 |
NCT06006286 | Phase Ib/II | ADI-PEG 20 + Atezolizumab + Bevacizumab | A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma | Withdrawn | USA | 0 |
NCT06034860 | Phase I | MT-8421 + Nivolumab MT-8421 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | Terminated | USA | 0 |
NCT06040099 | Phase II | Bevacizumab + Durvalumab | A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (EMERALD-Y90) | Recruiting | USA | 0 |
NCT06045975 | Phase II | Durvalumab + Tremelimumab Durvalumab | Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation (DUMELEP) | Recruiting | FRA | 0 |
NCT06056323 | Phase Ib/II | HB0045 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06084481 | Phase I | ABBV-400 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | Recruiting | USA | ISR | ESP | AUS | 4 |
NCT06084884 | Phase Ib/II | AZD5851 | A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma (ATHENA) | Recruiting | USA | 1 |
NCT06096779 | Phase II | Atezolizumab + Bevacizumab Atezolizumab | A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis (Kirros) | Recruiting | USA | 1 |
NCT06108050 | Phase I | JZP898 + Pembrolizumab JZP898 | JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT06109272 | Phase II | ABBV-151 + Budigalimab Atezolizumab + Bevacizumab Durvalumab + Tremelimumab | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) | Recruiting | USA | ITA | FRA | ESP | 2 |
NCT06218511 | Phase I | Durvalumab + IMA970A + Montanide ISA 51 | A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1) | Recruiting | ITA | 0 |
NCT06242470 | Phase I | MGC026 | A Study of MGC026 in Participants With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT06294548 | Phase Ib/II | Atezolizumab + Bevacizumab + DS-3201b | Phase Ib/II Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC | Not yet recruiting | USA | 0 |
NCT06330064 | Phase II | Ifinatamab deruxtecan | A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) | Recruiting | USA | TUR | POL | NLD | ITA | IRL | FRA | ESP | DEU | BRA | BEL | AUS | ARG | 5 |
NCT06337162 | Phase I | INCB099280 | Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC) (HCC) | Withdrawn | USA | 0 |
NCT06362369 | Phase Ib/II | 7HP349 + Ipilimumab + Nivolumab | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | Recruiting | USA | 0 |
NCT06391918 | Phase I | GEN2 + Valganciclovir | Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06427941 | Phase I | BGB-B2033 BGB-B2033 + Tislelizumab | A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | NZL | 1 |
NCT06478693 | Phase I | MT-303 | A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC | Recruiting | AUS | 0 |
NCT06514651 | Phase I | MAQ-001 Ipilimumab + MAQ-001 | MAQ-001 in Patients With Advanced Solid Tumors | Recruiting | FRA | 0 |
NCT06521567 | Phase Ib/II | Cobolimab + Dostarlimab-gxly | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | Not yet recruiting | USA | ITA | FRA | ESP | DNK | DEU | CZE | BRA | ARG | 1 |
NCT06526104 | Phase II | Durvalumab + Tremelimumab | Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis | Not yet recruiting | USA | 0 |
NCT06526338 | Phase II | IP-001 | Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone | Recruiting | USA | 0 |
NCT06533332 | Phase I | ERX-315 | A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors | Recruiting | AUS | 0 |
NCT06551272 | Phase II | Atezolizumab + Bevacizumab + EXL01 | Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma (MOTHER) | Not yet recruiting | FRA | 0 |
NCT06553885 | Phase II | Enfortumab vedotin-ejfv | Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC | Not yet recruiting | USA | 0 |
NCT06582017 | Phase I | QXL138AM | Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | Recruiting | USA | 0 |
NCT06596694 | Phase Ib/II | Patritumab deruxtecan | Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) | Recruiting | USA | ISR | 2 |
NCT06600321 | Phase I | ALN-BCAT + Pembrolizumab ALN-BCAT | A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma | Recruiting | USA | 0 |
NCT06608940 | Phase Ib/II | BC3402 + Durvalumab + Tremelimumab | BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma | Not yet recruiting | USA | 0 |